Chimeric antigen receptor T (CAR-T) cell therapy has emerged as a transformative approach in modern medicine, demonstrating remarkable efficacy in targeting pathogenic B-cell lineages with ...
How Does Zynlonta Work for B-Cell Lymphoma? Zynlonta is an antibody drug conjugate (ADC), which is a type of targeted cancer medicine. ADCs work as smart bombs to find cancer cells in the body that ...
SAVANNAH, Georgia — Inebilizumab, a first-in-class anti-CD19 B-cell depleting agent, demonstrated both safety and superior efficacy compared with placebo in patients with seropositive generalized ...
First implementation of artificial intelligence empowered all-in-one radiotherapy workflow for nasopharyngeal carcinoma. Longitudinal tracing of on-treatment plasma Epstein-Barr virus DNA as a ...
However, details of the intervening steps, as researchers have learned in the past 65 years, are quite complex — certain cells carry the flu antigen to the immune system, specific immune cells respond ...
More than a third of patients with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) treated with the CAR T-cell therapy obecabtagene autoleucel (obe-cel) remained in remission at a ...
Clinical Outcomes and Histologic Findings of Patients With Hepatocellular Carcinoma With Durable Partial Response or Durable Stable Disease After Receiving Atezolizumab Plus Bevacizumab The IELSG37 ...
New study demonstrates how high-affinity B cells 'bank' their best traits instead of rolling the dice and risking deleterious mutations, with implications for better vaccine design. A vaccine's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results